Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats

J Neural Transm (Vienna). 2009 Jul;116(7):867-74. doi: 10.1007/s00702-009-0242-9. Epub 2009 May 26.

Abstract

A decrease in noradrenergic activity in Parkinson's disease might play a critical role in long-term motor complications associated with chronic dopaminergic replacement. Using the rat model of parkinsonism with an additional noradrenergic degeneration induced by the N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) toxin we evaluated whether the circling motor activity and dose-failure episodes induced by levodopa (L-DOPA) differ between single (6-OHDA) and double (6-OHDA + DSP-4) denervated animals challenged with a single daily dose of L-DOPA. While single-lesioned animals showed a sensitization-desensitization turning response with a significant increase on day 15 and a decrease on day 22, in double-lesioned animals, the turning activity was maximal from day 1 and did not decay on day 22. Double-lesioned rats exhibited significantly higher number of turns on days 15 and 22 and a significantly lower percentage of dose-failure episodes during treatment. Noradrenergic denervation appears to be associated with prolonged long-term dopaminergic sensitization. This type of response appears to be comparable to that in the clinical setting with intermittent L-DOPA administration where no desensitization occurs once the abnormal response is established.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology
  • Benzylamines / toxicity
  • Brain / drug effects*
  • Brain / metabolism*
  • Brain / physiopathology
  • Disease Models, Animal
  • Dopamine / metabolism
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Interactions / physiology
  • Levodopa / pharmacology*
  • Male
  • Movement / drug effects
  • Movement / physiology
  • Neurotoxins / toxicity
  • Norepinephrine / metabolism*
  • Oxidopamine / toxicity
  • Parkinsonian Disorders / drug therapy*
  • Parkinsonian Disorders / metabolism*
  • Parkinsonian Disorders / physiopathology
  • Presynaptic Terminals / drug effects
  • Presynaptic Terminals / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Recovery of Function / drug effects
  • Recovery of Function / physiology
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology
  • Time
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Benzylamines
  • Neurotoxins
  • Levodopa
  • Oxidopamine
  • DSP 4
  • Dopamine
  • Norepinephrine